We also found that genetic and/or pharmacological BRAF inhibition suppressed MAPK pathway activation and attenuated LAT1 expression in BRAF V600E-mutated-PLNTY cells and -glioblastoma cell lines. The gene discussed is BRAF; the disease is glioblastoma.